JACC:高敏肌钙蛋白+冠脉CTA,确诊隐匿性冠心病的“黄金搭档”

2021-10-02 MedSci原创 MedSci原创

冠状动脉疾病(CAD)是全世界最常见的死亡原因。

冠状动脉疾病(CAD)是全世界最常见的死亡原因。许多CAD患者一直未被诊断,直到他们因急性胸痛到医院就诊。目前的评估策略主要是通过床边临床评估、心电图和连续的心肌肌钙蛋白检测来排除急性心肌梗死

然而,即使排除了急性心肌梗死,仍有相当一部分患者可能仍有潜在的CAD,并有将来发生不良心脏事件的风险。选择此类患者进行进一步检查的最佳方法仍不确定。

现在人们越来越认识到,高敏心肌肌钙蛋白(hs-cTnI)浓度在正常参考范围内可以帮助对疑似急性冠脉综合征患者进行分流。此前有专家确定并验证了5ng/L的排除阈值,该阈值可使疑似急性冠状动脉综合征患者在发病时被确定为低风险的人数达到最大化,且30天内心肌梗死或心脏死亡的阴性预测值大于99.5%。

为了评估hs-cTnI在排除心肌梗死后的患者选择进一步检查的作用,来自英国BHF血管科学中心的专家开展了一项前瞻性队列研究,相关结果发表在《美国心脏病学会》JACC杂志上。

研究对象为到急诊科就诊的疑似急性冠脉综合征患者,且hs-cTnI浓度低于特定性别的第99%。患者以2:1的方式招募,按hs-cTnI峰值浓度高于和低于5ng/L的风险分层阈值进行分层。所有患者在出院后都接受了冠状动脉计算机断层扫描(CCTA)。

总体而言,招募了250名患者(61.4±12.2岁,31%为女性),其中62.4%(250名患者中的156名)患有冠状动脉疾病(CAD)。与hs-cTnI浓度<5 ng/L的患者相比,hs-cTnI浓度中等的患者(介于5 ng/L和特定性别的第99百分位数之间)更有可能患有CAD,风险增加2.33倍(71.9% [120/167] vs 43.4% [36/83];OR= 3.33;95% CI:1.92-5.78)。

不同hs-cTnI浓度亚组发生CAD的风险

相反,心绞痛症状和CAD之间没有关联(63.2% [67/106] vs 61.8% [89/144];OR=0.92;95% CI:0.48-1.76)。大多数CAD患者以前没有诊断(53.2%;83/156),在接受CCTA之前没有使用抗血小板和他汀类药物治疗(63.5%;99/156)。

在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。

 

参考文献:

Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction. J Am Coll Cardiol. 2021 Oct, 78 (14) 1407–1417

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2022-05-09 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2022-09-07 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2021-10-04 许安
  8. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2021-10-04 1def6e10m76(暂无匿称)

    #心梗#在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。

    0

相关资讯

JAMA Psychiatry: 有氧运动或艾司西酞普兰治疗冠心病焦虑患者

艾司西酞普兰对患有冠心病的焦虑患者是安全有效的,同时有氧运动对改善冠心病患者焦虑有益

EHJ:孰优孰略?冠脉三支病变或左主干病变患者介入与开胸手术的比较

在3VD和/或LMCAD患者中,MAG可能是更理想的CABG配置,以实现比PCI更低的长期全因死亡率。

护士主导的电子健康护理干预措施能够改善冠心病患者预后

护士主导的电子健康心脏康复计划对改变行为风险因素及提高健康相关生活质量有效。

梅斯心血管疾病进展 (009期)

编者按:梅斯医学将定期进行汇总,帮助大家概览心血管领域最新进展。下面是呈现给大家的最新一期的心血管进展。enjoy~

JAMA Psychiatry:当心!冠心病患者可能得了“双心病”!

艾司西酞普兰治疗焦虑对减少冠心病患者的焦虑是安全和有效的。

拓展阅读

收藏!冠心病的治疗策略与药物选择,看这一篇就够了

药物治疗是冠心病治疗的基础,其贯穿治疗始终。根据我国和欧美稳定性冠心病诊治指南冠心病常用药物包括改善缺血、减轻症状的药物,抗血小板药物,稳定斑块的药物,改善心肌能量代谢的药物,改善心肌重构的药物等。

Hypertension:血浆甘氨酸和支链氨基酸之间的相互作用与高血压和冠心病有关

总支链氨基酸/甘氨酸比率是高血压和CHD代谢特征的关键因素,可能反映了甘氨酸和tBCAAs共享了生物学途径。

中医标杆、循证引领丨《通心络防治冠心病临床应用中国专家共识》重磅发布

《通心络防治冠心病临床应用中国专家共识》在第二十七届中国医师协会介入心脏病学大会(CCIF 2024)暨第十三届中国胸痛大会(CCPCC 2024)期间正式发布。

韩雅玲院士团队:2023年度冠心病抗栓治疗领域的研究进展

本文将简要解读和分析2023年冠心病介入抗栓治疗领域最新突破性临床研究的主要结果,以及临床实践指南中关于抗栓治疗的更新要点,为今后我国冠心病抗栓领域的创新和探索提供参考。

胸闷病人前降支近段闭塞!开通过程又发生严重无复流!回旋支中段和右冠远段闭塞下次再处理吧!

患者女性,74岁,一过性晕厥3小时,伴有胸闷腹痛。既往有高血压、冠心病。

粗大右冠脉中段支架后1小时近端急性闭塞

患者男性,60岁,主因间断胸痛8天,加重2天于2022-10-08 10:15入院。体重78.15kg,身高173cm,BMI 26.11kg/m²。